{"id":"W4385644849","doi":"10.1097/01.hs9.0000967680.90062.ca","title":"S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); CD38; Gastroenterology; Lenalidomide; Multiple myeloma; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002198194,0.0004931265,0.001231924,0.0005372154,0.0001930314,0.001043714,0.0005906485,0.0005495831,0.00372992],"category_scores_gemma":[0.001510323,0.0001804658,0.00184896,0.0007991669,0.0001445328,0.0005455309,0.0004033104,0.000696841,0.0009927833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006139,"about_ca_system_score_gemma":0.0007712013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001797965,"about_ca_topic_score_gemma":0.004624998,"domain_scores_codex":[0.9992716,0.0002557034,0.00009902759,0.0001012704,0.0001865123,0.00008595694],"domain_scores_gemma":[0.9989599,0.0002189602,0.0003398661,0.00004455888,0.0002468387,0.0001897982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08775925,0.001738688,0.1680615,0.006539288,0.01016088,0.0008684214,0.0003329404,0.003888804,0.01462071,0.0003245314,0.0538687,0.6518363],"study_design_scores_gemma":[0.02801028,0.05936745,0.6817443,0.002762839,0.02387847,0.005446217,0.0003678967,0.004639166,0.01358001,0.0006906331,0.1793257,0.0001871541],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8545604,0.09283523,0.00157151,0.004566837,0.0006554187,0.00103721,0.02370281,0.0003548721,0.02071577],"genre_scores_gemma":[0.9265093,0.02285862,0.003412579,0.004272564,0.0007700464,0.0005630814,0.03732314,0.0001124742,0.00417812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00372992,"threshold_uncertainty_score":0.01247782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02095778794704758,"score_gpt":0.2764088675186831,"score_spread":0.2554510795716355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}